SB17
Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America
September 11, 2023Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
